Retransplantace u nemocnych s mnohocetnym myelomem.

High doses of chemotherapy followed by autologous transplantation became widespreadly indicated as upfront therapy for patients with multiple myeloma (MM) in the last decade, with very good tolerance and low mortality. MM remains unfortunately incurable and the relaps of the disease is unavoidable. Therapy of relapsing MM is still considered to be experimental. The principle of T2 model is a repeated transplantation therapy with testing different experimental approaches in patients with MM relapsing/progressing after the 1st autologous transplantation (AT). The patients are treated with the same + something more - same or very similar induction and reinduction treatment, same myeloablative regimen in the 1st and the 2nd AT and a different maintenance, experimental therapy after the 2nd AT. The evaluation of the results of each therapeutic approach uses the intra-individual analysis - the comparison of event free survival I (EFS I) (after the 1st AT) and EFS II (after the 2nd AT) in one patient. In T2 model both EFS I and EFS II are compared in one patient, therefore the individual differences are excluded.Available from STL Prague, CZ / NTK - National Technical LibrarySIGLECZCzech Republi